Pfizer and Valneva say their VLA15 Lyme vaccine is showing promise in late‑stage trials; a Phase 3 readout is expected in early 2026.

Abbott has closed its roughly $21B purchase of Exact Sciences, paying $105 a share and folding Cologuard and other cancer‑testing assets into its diagnostics arm while keeping Exact’s Madison operations intact.

An international drilling mission found low‑salinity water trapped beneath the Atlantic off New England. Early estimates say the supply could be huge — but tapping it would be complex.

Merlin Labs went public this week via a SPAC merger, listing on Nasdaq under MRLN and closing at $9.03. The Boston startup arrives with fresh capital and a $105M defense contract to accelerate hiring and certification.

Goldman Sachs is investing $42.5M in Chicago‑based GeoWealth to extend its Series C and deepen a product partnership aimed at RIAs.

Congress moved to restore SBIR/STTR authority, reopening non‑dilutive R&D grants that many New York biotech startups rely on.

New reporting shows Epstein paid consultants and used fake sites and Wikipedia edits to bury negative search results and burnish a philanthropic image.

Pfizer reported mid‑stage results showing atirmociclib plus fulvestrant cut progression or death risk by about 40% in patients previously treated with CDK4/6 inhibitors.

A viral cellphone clip from Corona shows three glowing orbs moving in a triangular pattern. Authorities say corroborating radar or sensor data are needed to identify the sighting.

UT Austin researchers built a near-atomic map of the Andes hantavirus and produced a vaccine candidate that triggered neutralizing antibodies in mice.

Gracenote sued OpenAI in Manhattan, alleging its curated media metadata was copied to train ChatGPT. The suit says the company's database structure was used without permission.

Federal probes into banks' AI hiring tools raise questions about bias in résumé screeners. Here’s what researchers and regulators are watching and how applicants can respond.

Perplexity asked a federal judge to narrow parts of suits by The New York Times and Chicago Tribune while leaving core copyright allegations intact.